YD Bio Limited (NASDAQ:YDES – Get Free Report) CEO Ethan Phd Shen purchased 3,100 shares of YD Bio stock in a transaction that occurred on Wednesday, September 9th. The shares were bought at an average cost of $3.93 per share, with a total value of $12,183.00. Following the completion of the transaction, the chief executive officer directly owned 11,245,631 shares of the company’s stock, valued at approximately $44,195,329.83. The trade was a 0.03% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
YD Bio Stock Performance
Shares of YDES opened at $3.90 on Friday. The company’s fifty day simple moving average is $2.98 and its 200 day simple moving average is $4.53. YD Bio Limited has a 1-year low of $1.70 and a 1-year high of $25.00.
YD Bio (NASDAQ:YDES – Get Free Report) last issued its earnings results on Tuesday, September 1st. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter. The firm had revenue of $0.42 million during the quarter.
Institutional Trading of YD Bio
YD Bio Company Profile
YD Bio Limited is a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations.
Read More
- Five stocks we like better than YD Bio
- AeroVironment’s Record Backlog and Earnings Beat Fuel Recovery Case
- Corning Just Locked In a Massive Verizon Fiber Deal as AI Infrastructure Expands
- 3 Under-$20 Stocks Tied to the Future of U.S. Energy and Materials
- Uncle Sam’s Quantum Leap: Feds Fund a $300M Quantum Supercycle
Receive News & Ratings for YD Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for YD Bio and related companies with MarketBeat.com's FREE daily email newsletter.
